公开(公告)号：US09669036B2

公开(公告)日：2017-06-06

申请号：US14891200

申请日：2014-05-14

申请人： THE UNIVERSITY OF CHICAGO

发明人： Bernard Roizman ,  Guoying Zhou ,  Te Du

IPC分类号： A61K31/5377 ,  A61K31/12 ,  A61K31/165 ,  A61K31/167 ,  A61K45/06 ,  A61K31/255 ,  A61K31/40 ,  A61K31/4192 ,  A61K31/4402 ,  A61K31/185 ,  A61K31/4045 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4406 ,  A61K31/4745 ,  A61K31/517

CPC分类号： A61K31/5377 ,  A61K31/12 ,  A61K31/165 ,  A61K31/167 ,  A61K31/185 ,  A61K31/255 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/4192 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4745 ,  A61K31/517 ,  A61K45/06

摘要： The disclosure relates to methods of controlling the state of a virus (lytic or lysogenic) in an individual, such as a method of reactivating a latent virus in an individual, comprising administering one or more agents that modulates the activity of signal transducer and activator of transcription 3 (STAT3) or any of p300, CBP or p300/CBP. Also contemplated are methods further comprising administering an HDAC modulating agent, such as an HDAC inhibiting agent or an HDAC activating agent.

公开(公告)号：US10561708B2

公开(公告)日：2020-02-18

申请号：US15975396

申请日：2018-05-09

申请人： The University of Chicago

发明人： Nikolai Khodarev ,  Ravi Sood ,  Bernard Roizman ,  Ralph R. Weichselbaum

IPC分类号： A61K38/17 ,  A61K31/506 ,  A61K45/06

摘要： Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more inhibitors of the JAK/STAT pathway which renders the cancer chemosensitive and/or radiosensitive.

公开(公告)号：US09803006B2

公开(公告)日：2017-10-31

申请号：US14589581

申请日：2015-01-05

申请人： THE UNIVERSITY OF CHICAGO

发明人： Guoying Zhou ,  Bernard Roizman

IPC分类号： C07K14/00 ,  C07K16/18 ,  A61K47/48 ,  C07K14/54 ,  A61K38/20 ,  C12N15/869 ,  C12N15/86 ,  C12Q1/70 ,  A61K35/00

CPC分类号： C07K16/18 ,  A61K35/00 ,  A61K38/2086 ,  A61K47/642 ,  A61K47/6801 ,  A61K47/69 ,  A61K47/6901 ,  C07K14/5437 ,  C12N15/86 ,  C12N15/8695 ,  C12N2710/16632 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2799/028 ,  C12N2810/50 ,  C12N2810/852 ,  C12Q1/705

摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.

公开(公告)号：US20160089376A1

公开(公告)日：2016-03-31

申请号：US14891200

申请日：2014-05-14

申请人： THE UNIVERSITY OF CHICAGO

发明人： Bernard Roizman ,  Guoying Zhou ,  Te Du

IPC分类号： A61K31/5377 ,  A61K31/185 ,  A61K31/4406 ,  A61K31/40 ,  A61K31/12 ,  A61K31/4745 ,  A61K31/255 ,  A61K31/4045 ,  A61K31/517 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/167 ,  A61K31/4192

CPC分类号： A61K31/5377 ,  A61K31/12 ,  A61K31/165 ,  A61K31/167 ,  A61K31/185 ,  A61K31/255 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/4192 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4745 ,  A61K31/517 ,  A61K45/06

摘要： The disclosure relates to methods of controlling the state of a virus (lytic or lysogenic) in an individual, such as a method of reactivating a latent virus in an individual, comprising administering one or more agents that modulates the activity of signal transducer and activator of transcription 3 (STAT3) or any of p300, CBP or p300/CBP. Also contemplated are methods further comprising administering an HDAC modulating agent, such as an HDAC inhibiting agent or an HDAC activating agent.

摘要翻译： 本公开涉及控制个体中病毒（溶解或溶解性）状态的方法，例如重新激活个体中的潜伏病毒的方法，包括施用一种或多种调节信号转导子和活化剂的活性的试剂 转录3（STAT3）或p300，CBP或p300 / CBP中的任何一种。 还考虑的方法还包括施用HDAC调节剂，例如HDAC抑制剂或HDAC活化剂。

公开(公告)号：US20170298362A1

公开(公告)日：2017-10-19

申请号：US15636952

申请日：2017-06-29

申请人： THE UNIVERSITY OF CHICAGO

发明人： Nikolai Khodarev ,  Ravi Sood ,  Bernard Roizman ,  Ralph Weichselbaum

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K31/506 ,  C12Q1/68 ,  A61K31/519 ,  A61K45/06

CPC分类号： C12N15/1137 ,  A61K31/506 ,  A61K31/519 ,  A61K31/713 ,  A61K45/06 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/12 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158

摘要： Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.

公开(公告)号：US20130150258A1

公开(公告)日：2013-06-13

申请号：US13734527

申请日：2013-01-04

申请人： The University of Chicago

发明人： Ralph Weichselbaum ,  Bernard Roizman ,  Andy Minn ,  Nikolai Khodarev ,  Edwardine Labay

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2800/52

摘要： Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.

摘要翻译： 公开了一组在化学疗法和耐辐射肿瘤中差异表达的基因，可用于预测治疗反应和评估癌症患者局部局部衰竭，存活和转移的风险。 还公开了根据基因表达表征肿瘤的方法和用于本发明方法的试剂盒。

公开(公告)号：US20190071679A1

公开(公告)日：2019-03-07

申请号：US16179577

申请日：2018-11-02

申请人： THE UNIVERSITY OF CHICAGO

发明人： Nikolai Khodarev ,  Ravi Sood ,  Bernard Roizman ,  Ralph Weichselbaum

IPC分类号： C12N15/113 ,  A61K45/06 ,  C12Q1/6886 ,  A61K31/713 ,  A61K31/506 ,  A61K31/519

摘要： Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.

公开(公告)号：US20180256678A1

公开(公告)日：2018-09-13

申请号：US15975396

申请日：2018-05-09

申请人： The University of Chicago

发明人： Nikolai Khodarev ,  Ravi Sood ,  Bernard Roizman ,  Ralph R. Weichselbaum

IPC分类号： A61K38/17 ,  A61K45/06 ,  A61K31/506

CPC分类号： A61K38/177 ,  A61K31/506 ,  A61K45/06

摘要： Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more inhibitors of the JAK/STAT pathway which renders the cancer chemosensitive and/or radiosensitive.

公开(公告)号：US20160175370A1

公开(公告)日：2016-06-23

申请号：US14589581

申请日：2015-01-05

申请人： THE UNIVERSITY OF CHICAGO

发明人： Guoying Zhou ,  Bernard Roizman

IPC分类号： A61K35/763 ,  C07K16/18 ,  C07K14/54 ,  C12N7/00 ,  A61K47/48

CPC分类号： C07K16/18 ,  A61K35/00 ,  A61K38/2086 ,  A61K47/642 ,  A61K47/6801 ,  A61K47/69 ,  A61K47/6901 ,  C07K14/5437 ,  C12N15/86 ,  C12N15/8695 ,  C12N2710/16632 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2799/028 ,  C12N2810/50 ,  C12N2810/852 ,  C12Q1/705

摘要： The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.

摘要翻译： 本发明涉及靶向一种或多种特异性结合对成员（例如受体）的工程化单纯疱疹病毒（HSV）颗粒。 此外，提供了用于生产这种HSV颗粒的重组载体。 通过降低HSV对其天然受体的亲合力并增加对所选受体的亲和力，本发明的HSV颗粒可用于靶向表达所选受体的细胞，其本身可能是遗传工程的产物。 选择性靶向细胞的能力使HSV颗粒特别适用于选择性诊断，治疗和成像携带所选结合对成员（如受体）的细胞。 本发明还提供了携带选定结合对成员例如受体的细胞的基于多核苷酸的治疗。